Fig. 10

A Schematic illustration of a multipronged nanocomplex (pHA-NC) preparation and the mechanism for ROS self-sufficient oxidation therapy of cancers. B H₂O₂ production from different formulations in pH 7.4 PBS solution. C Relative ROS levels in B16F10 cells incubated with different formulations and times were measured by flow cytometry after DCFH-DA staining. D Fluorescence imaging of ROS generation in differently treated B16F10 tumor-bearing mice at 1, 6, 12 and 24 h, which were intratumorally injected as an indicator of ROS with DCFHDA (2.5 mg/kg) before intravenous injection of saline (I), pHA-NC (II) and HA-NC (III) at a dose of 2.5 mg/kg MLT. E Representative images of B16F10 xenograft tumors in mice after different treatments on day 12. F Tumor growth curves of mice after different treatments (n = 5). G Body weight changes in B16F10 tumor-bearing mice during treatments (n = 5). H Animal survival rates after different treatments. Reproduced with permission from [144].